Dysregulation of the mTOR pathway has been related to tumorigenesis, poor prognosis and/or chemotherapy resistance in several malignancies including leukemia. 3, 4 Inhibition of mTORC1 by rapamycin and its analogs has been explored to treat tumors from various cellular origins. However, the effectiveness of patient response is limited and not all patients respond. [5] [6] [7] [8] Second generation of mTOR inhibitors have recently been developed to target mTOR kinase activity and to suppress both mTORC1 and mTORC2. 9, 10 Fanconi anemia (FA) is a genomic instability syndrome that is defective for a DNA damage response pathway resulting in cellular hypersensitivity to DNA-damaging agents. 11 Mutation or silencing of genes controlling the FA pathway has been linked to reduced genomic stability and is associated with increased drug sensitivity. 12 Therefore, inhibition of the FA pathway combined with DNA-damaging anticancer drugs may represent a promising strategy for cancer therapy.
To explore the therapeutic value of dual mTORC1 and mTORC2 inhibitor in tumor suppression, we treated human T-ALL (T-cell acutelymphoblastic leukemia) cell line Molt-Luc2 with pp242, an mTOR kinase inhibitor, the anticancer drug AraC or etoposide, or the combination of pp242 with AraC or etoposide. We found that the combination of pp242 with AraC or etoposide reduced survival of all of these cells to a greater extent than AraC or etoposide alone (Figure 1a ). On the other hand, Molt-Luc2 cells treated with the combination of rapamycin with AraC or etoposide showed comparable survival rate to that treated with AraC or etoposide alone (Figure 1a ). The combination of pp242, but not rapamycin, with AraC or etoposide induced significant higher apoptosis than single-agent treatment (Figure 1b and Supplementary Figure 1A) . Specifically, the percentage of apoptotic Molt-Luc2 cells for combined pp242-AraC and pp242-etoposide treatments were 76.3 ± 4.2% and 78.2 þ 5.9%, respectively, in comparison with 52.7±6.3% and 38.2±4.5%, respectively, in AraC-and etoposide-treated cells. Moreover, Molt-Luc2 cells treated with the combination of pp242 and the DNA crosslinker anticancer drug cisplatin were more susceptible to apoptosis than that treated with single agent (Supplementary Figure 1B) . Consistent with pp242, AZD8055 or INK128, two other mTOR kinase inhibitors, also sensitized Molt-Luc2 cells for AraC-induced apoptosis (Supplementary Figure 1C) . Mechanistically, pp242, AZD8055 or INK128, but not rapamycin, sensitized Molt-Luc2 cells to DNA damage induced by AraC, etoposide or cisplatin, evidenced by a marked increase in gH2AX foci (for example, 94±5% cells in pp242-AraC group vs 25±3% cells in AraC alone group or 98 ± 4% cells in pp242-etoposide group vs 36 ± 3% cells in etoposide alone group; Figure 1c and Supplementary Figures 2A  and B) , as well as DNA-strand breaks (olive tail moment of 25.4±1.2 in pp242-AraC group and 31.2±3.2 in pp242-etoposide group compared with 9.8±1.2 in AraC alone and 11.4±2.8 in etoposide alone groups, respectively; Figure 1d ).
To gain insight into potential mechanisms underlying the observed increase in apoptosis and DNA damage induced by mTOR-chemotherapy, we analyzed mTOR kinase inhibitor-induced molecular changes. As expected, pp242, AZD8055, INK128, and another dual mTORC1 and mTORC2 inhibitor Torin 1, inhibited the phosphorylation of mTOR downstream signaling molecules S6 and 4E-BP1 (Figure 1e and Supplementary Figure 3A) . Although rapamycin was reported to induce a compensatory activation of Akt and extracellular signal-regulated kinases 1 and 2 (ERK1/2), Figure 3C ), 14 suggesting that the suppression of FANCD2 expression by dual mTORC1 and mTORC2 inhibitors (pp242, AZD8055 and INK128) is not an off-target effect. In line with that mTORC1 inhibitor, rapamycin had no effect on FANCD2 expression on both shortterm and long-term treatment of Molt-Luc2 cells (Figure 1f ), these data indicate that mTORC2 is essential for mTOR regulation of FANCD2 expression. Interestingly, pp242 did not inhibit the expression of other FA proteins such as FANCA and FANCC (Supplementary Figure 3D) , suggesting that the effect of pp242 on FA gene expression was FANCD2 specific. To ensure that the effect of pp242 was mediated by suppression of FANCD2 expression, we carried out rescue experiments by forced expression of FANCD2 driven by a viral promoter in Molt-Luc2 cells. As our results showed that suppression of FANCD2 expression by pp242 was transcriptional, we reasoned that pp242 would likely not affect an ectopic FANCD2 expression driven by a viral promoter. Indeed, treatment of the empty vector-or FANCD2-transduced cells with pp242 reduced endogenous FANCD2 but had no effect on virally expressed FANCD2 (Figure 1g ). Remarkably, exogenous FANCD2 expression effectively reduced apoptosis and DNA damage (g-H2AX foci formation) in cells treated with both pp242 and AraC to nearly similar levels as in cells treated with AraC alone (Figures 1h and i) . These results substantiate the notion that suppression of FANCD2 expression by pp242 is responsible for the augmented effect elicited by combined treatment with pp242 and AraC.
To determine whether pp242 could enhance the efficacy of chemotherapy in vivo, we administrated a combination of pp242
Accepted article preview online 15 July 2013; advance online publication, 2 August 2013 Letters to the Editor or rapamycin with the anticancer drug AraC to two xenotransplant models: Molt-Luc2 T-ALL cell line and primary T-ALL patient cells. We first examined the effect of combined pp242 and AraC therapy in NSG NOD SCID gamma recipient mice transplanted with MoltLuc2 T-ALL cell line. We found that combined pp242-AraC, but not rapamcyin-AraC, significantly prolonged life span of Molt-Luc2 cellxenografted mice (Figures 2a and b) , compared with single-agent treatment. The combination of pp242 and AraC markedly reduced tumor cells in vivo compared with AraC alone, as observed by IVIS imaging system (Caliper, Hopkinton, MA, USA) (Figure 2c ). It is noteworthy that leukemia cells were suppressed by AraC alone up to 2 weeks post-treatment but rapidly came back several days later in this xenotransplant model, and that combined pp242-AraC treatment significantly delayed the relapse of the leukemia (Figures 2b and c) . Accordingly, xenografted leukemic cells from pp242-AraC-treated mice exhibited increased apoptosis (Figure 2d ) and DNA damage (Figure 2e) , accompanied by decreased expression of FANCD2 (Figure 2f ). Molt-Luc2 cells were transduced with mock vector or FANCD2 by retroviral infection, and the cells were then pre-treated with or without pp242 (2.4 mM) for 3 h, followed by incubation with or without AraC (10 mM) for additional 24 h. FANCD2 expression was examined by western blotting. Topo1 was blotted as loading control (g). Apoptotic cells were determined by Annexin V and 7-AAD staining followed by flow cytometry analysis (h). gH2AX content was examined by flow cytometry and mean fluorescence intensity (MFI) was shown (i). *Po0.05; **Po0.01. Error bars represent mean ± s.e.m.
We next determined whether the combined pp242 therapy was also effective in primary T-ALL patient cell-xenografted mice. NSG mice were engrafted with a primary T-ALL patient sample, and secondary transplantation was performed to expand cohorts for study. The recipient mice treated with vehicle or single-agent AraC or pp242 died of leukemia within 80 days; whereas mice treated with combined pp242-AraC showed significantly prolonged survival (Figure 2g ). Taken together, these results show that combined pp242-AraC treatment produces enhanced anti-leukemic effect in T-ALL xenotransplant models.
Our studies suggest that the mTOR kinase inhibitor can enhance antitumor activity of conventional chemo-drugs in vitro and in vivo by suppressing FANCD2, and consequently augmenting DNA damage leading to apoptosis. Therefore, the new generation mTOR kinase inhibitors combined with conventional chemotherapy could represent a new strategy for the treatment of T-ALL. 15 In addition, since the FA pathway is a DNA damage response pathway required for cellular resistance to anticancer drug-induced DNA damage, 11, 12 our findings imply that inhibition of the FA pathway coupled with chemotherapy may be useful for cancer treatment. 
